The initial product that Sealonix is developing is a sealant patch providing rapid hemostasis for abdominopelvic and orthopedic procedures.
Sealonix announced today that it has closed a $20 million Series A financing. The round was led by Excelestar Ventures with additional participation from AMED Ventures, Sparta Group, Iyengar Capital, J2 Ventures and TiE Boston.
Sealonix is using its biomaterials expertise to develop next generation hemostatic sealants for surgical use. The initial product that Sealonix is developing is a sealant patch providing rapid hemostasis for abdominopelvic and orthopedic procedures. The PramStat patch is designed to bioabsorb within a week following implantation. The proceeds from this round will be used to grow the development team and execute clinical trials.
Dr. William Spotnitz, Professor of Surgery at the University of Virginia Health System with over 20 years in hemostat device research, noted, "Obtaining hemostasis with existing approved devices during surgical procedures can be a challenging and time-consuming task. The PramStat patch has the potential to drastically reduce this time as well as instill confidence in the durability of the hemostatic seal."
"At Excelestar, we are excited to partner with Sealonix's experienced team to bring this next generation hemostatic sealant to market," said Tasneem Dohadwala, Founding Partner at Excelestar Ventures, who will also be joining Sealonix's Board of Directors.
Amar Sawhney, Sealonix CEO, commented, "The PramStat patch builds on many years of research done by this experienced team, and now will move rapidly into clinical development. This capital will allow us to complete clinical development and pursue FDA approval. We look forward to bringing the most advanced device and method to control surgical bleeding to surgeons."
About Sealonix, Inc: Sealonix, Inc. is a privately held company based in Bedford, MA focused on the development and commercialization of hemostatic sealants using its proprietary biomaterials. The company, founded in January 2023, is the latest by serial entrepreneur Amar Sawhney who also founded Confluent Surgical, Ocular Therapeutix, Augmenix,, Instylla, and Rejoni among others. More information about Sealonix can be found at http://www.sealonix.com
About Excelestar Ventures Founded in 2009, Excelestar Ventures invests in disruptive businesses led by under-represented founders including minorities and women. Excelestar Ventures generally invests in a strong team leading a B2B company, either in tech or medical devices, that has a clear, disruptive technology. www.excelestarventures.com
SOURCE Sealonix Inc
FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals
Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives. If your company has business or financial objectives check out: Strategic advisory services provided by FC Global Strategies Medical and Pharma Insider’s AI Connect Marketing Program Click here to schedule a complimentary call to discuss your company's business and financial goals.
Medical and Pharma Insider is a program of FC Global Strategies. FC Global Strategies' Contacts North America and Latin America Jeffrey Friedland, +1 646 450 8909 The Middle East, North Africa and Eastern Europe David Krutonog, +972 50 974 3429 Southeast Asia, Asia-Pacific, Australia, and New Zealand Ross Swan, +65 9181 9472